A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

Also called NCT02087917

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 376 participants (enrolled count) (from the registry)
Sponsor
  • Covance Registry lists this organization as a collaborator
Registry
  • NCT NCT02087917
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02087917. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2014-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Condition
Primary Hypercholesterolemia
Intervention (Drug)
HS-25
Intervention (Drug)
Placebo
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd. (class: industry)
Collaborator
Covance (class: industry)

Record details

Record id
cardio:ct-nct02087917
Content hash
ed66e24f783583a0293254d06ad9f6e5f15ea2be4d9f976710accc500edc4841